Welcome to our dedicated page for Jaguar Health news (Ticker: $JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jaguar Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jaguar Health's position in the market.
Rhea-AI Summary
Jaguar Health, Inc. announces an extension of the grace period by Nasdaq for regaining compliance with the $1.00 bid price requirement. The company's phase 3 OnTarget trial of crofelemer for preventing cancer therapy-related diarrhea is ongoing, with top-line results expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
-
News
Rhea-AI Summary
Jaguar Health, Inc. appoints Dr. Massimo Radaelli as President of Jaguar International, focusing on expanding commercial footprint globally. Dr. Radaelli's expertise in the pharmaceutical industry and rare disease therapies brings valuable leadership to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
-
Rhea-AI Summary
Jaguar Health, Inc. reported a decrease in net revenue for the year ended December 31, 2023, compared to 2022. The company's phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea is ongoing, with top-line results expected soon. Financially, there was a decrease in net revenue, loss from operations, and net loss attributable to common stockholders. However, interest expenses decreased, and there was a gain on extinguishment of debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.35%
Tags
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) will hold an investor webcast on April 1, 2024, to discuss fourth-quarter 2024 financials and corporate updates. The company plans to file its Earnings Report on April 1, 2024, on Form 10-K for the year ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
-
Rhea-AI Summary
Jaguar Health, Inc. announced a binding term sheet with Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret, A.S. for the exclusive license and commercialization of crofelemer. The agreement includes a $2 million investment by GEN in Jaguar stock, double-digit royalties to Jaguar on all crofelemer products sold, and manufacturing and marketing rights for various indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.97%
Tags
-
Rhea-AI Summary
Jaguar Health, Inc. (JAGX) provides an update on its Nasdaq listing status, facing potential delisting due to low stock prices. The company has requested a hearing, and the stock will continue trading pending the appeal decision. Jaguar is working on data analysis for its Phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea prevention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
Rhea-AI Summary
Jaguar Health, Inc. (JAGX) announces agreement with FDA for a clinical field study of Canalevia-CA1, a prescription drug for chemotherapy-induced diarrhea (CID) in dogs. The drug received conditional approval in December 2021 and is the first of its kind. The study aims for full approval by collecting evidence of effectiveness. Canalevia-CA1 helps dogs undergoing chemotherapy by improving comfort and quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
-
Rhea-AI Summary
Jaguar Health, Inc. (JAGX) donates plant-based drug Mytesi to Direct Relief, a humanitarian aid organization, to expand access to healthcare globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
-
Rhea-AI Summary
Jaguar Health (JAGX) submits an Orphan Drug Designation application to the FDA for crofelemer, a plant-based drug, for the treatment of cholera-related diarrhea. The company aims to address rare diseases with crofelemer and expects results from proof-of-concept studies for microvillus inclusion disease (MVID) and short bowel syndrome (SBS) by 2025. Crofelemer has been granted ODD for MVID and SBS by the FDA and EMA. The potential market exclusivity and development incentives for crofelemer are highlighted, targeting a significant global health issue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
Rhea-AI Summary
Jaguar Health, Inc. announced a preclinical study by Magdalena Biosciences, Inc. indicating psychoactive activity in a plant extract for mental health conditions such as ADHD, depression, and anxiety. The study shows potential for a next-generation psychoactive prescription drug candidate for treatment of mental health disorders. Magdalena aims to submit an Investigational New Drug (IND) application to the FDA in 2024 and enter the clinic with at least one botanical drug candidate. This comes as the World Health Organization estimates mental disorders to affect one in four people worldwide, with costs associated with lost productivity expected to reach $16 trillion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
Jaguar Health, Inc.
Nasdaq:JAGX
JAGX Rankings
JAGX Stock Data
73.27M
274.29M
1.78%
0.45%
8.5%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SAN FRANCISCO
About JAGX
jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/